MET and neoplasm: Total, in 4149 patients with 12 tumor types treated with immune checkpoint inhibitors, MET mutation (n = 206) decreased the risk of death by 39% (HR = 0.61; 95% CI, 0.50–0.74; P < 0.001; Fig. 1C).